Cargando…
The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies
BACKGROUND: Myeloperoxidase (MPO) is an endogenous oxidant enzyme that produces reactive oxygen species (ROS) and may be involved in lung carcinogenesis. The MPO−463G>A polymorphism influences MPO transcription and has been associated with lung cancer susceptibility. However, the association betw...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688689/ https://www.ncbi.nlm.nih.gov/pubmed/23840365 http://dx.doi.org/10.1371/journal.pone.0065778 |
_version_ | 1782476244749647872 |
---|---|
author | Yang, Jun-Ping Wang, Wen-Bo Yang, Xiao-Xi Yang, Lei Ren, Li Zhou, Fu-Xiang Hu, Liu He, Wei Li, Bai-Yu Zhu, Yan Jiang, Huan-Gang Zhou, Yun-Feng |
author_facet | Yang, Jun-Ping Wang, Wen-Bo Yang, Xiao-Xi Yang, Lei Ren, Li Zhou, Fu-Xiang Hu, Liu He, Wei Li, Bai-Yu Zhu, Yan Jiang, Huan-Gang Zhou, Yun-Feng |
author_sort | Yang, Jun-Ping |
collection | PubMed |
description | BACKGROUND: Myeloperoxidase (MPO) is an endogenous oxidant enzyme that produces reactive oxygen species (ROS) and may be involved in lung carcinogenesis. The MPO−463G>A polymorphism influences MPO transcription and has been associated with lung cancer susceptibility. However, the association between the MPO−463G>A polymorphism and lung cancer risk remains controversial. METHOD: To investigate the effect of this polymorphism on lung cancer susceptibility, we performed a meta-analysis based on 22 published case–control studies including 7,520 patients with lung cancer and 8,600 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. RESULTS: Overall, there was no evidence for significant association between MPO−463G>A polymorphism and lung cancer susceptibility (for AA versus GG: OR = 0.91, 95%CI = 0.67–1.24; for GA versus GG: OR = 0.87, 95% CI = 0.78–0.98; for AA/GA versus GG: OR = 0.90, 95% CI = 0.80–1.01; for AA versus GA/GG: OR = 0.96, 95% CI = 0.72–1.28). In the stratified analyses by ethnicity, source of controls and smoking status, we also did not find any significant association between them. CONCLUSIONS: In summary, this meta-analysis suggests MPO−463G>A polymorphism may not be a risk factor for developing lung cancer. However, further prospective well-designed population-based studies with larger sample size are expected to validate the results. |
format | Online Article Text |
id | pubmed-3688689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36886892013-07-09 The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies Yang, Jun-Ping Wang, Wen-Bo Yang, Xiao-Xi Yang, Lei Ren, Li Zhou, Fu-Xiang Hu, Liu He, Wei Li, Bai-Yu Zhu, Yan Jiang, Huan-Gang Zhou, Yun-Feng PLoS One Research Article BACKGROUND: Myeloperoxidase (MPO) is an endogenous oxidant enzyme that produces reactive oxygen species (ROS) and may be involved in lung carcinogenesis. The MPO−463G>A polymorphism influences MPO transcription and has been associated with lung cancer susceptibility. However, the association between the MPO−463G>A polymorphism and lung cancer risk remains controversial. METHOD: To investigate the effect of this polymorphism on lung cancer susceptibility, we performed a meta-analysis based on 22 published case–control studies including 7,520 patients with lung cancer and 8,600 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. RESULTS: Overall, there was no evidence for significant association between MPO−463G>A polymorphism and lung cancer susceptibility (for AA versus GG: OR = 0.91, 95%CI = 0.67–1.24; for GA versus GG: OR = 0.87, 95% CI = 0.78–0.98; for AA/GA versus GG: OR = 0.90, 95% CI = 0.80–1.01; for AA versus GA/GG: OR = 0.96, 95% CI = 0.72–1.28). In the stratified analyses by ethnicity, source of controls and smoking status, we also did not find any significant association between them. CONCLUSIONS: In summary, this meta-analysis suggests MPO−463G>A polymorphism may not be a risk factor for developing lung cancer. However, further prospective well-designed population-based studies with larger sample size are expected to validate the results. Public Library of Science 2013-06-20 /pmc/articles/PMC3688689/ /pubmed/23840365 http://dx.doi.org/10.1371/journal.pone.0065778 Text en © 2013 Yang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Yang, Jun-Ping Wang, Wen-Bo Yang, Xiao-Xi Yang, Lei Ren, Li Zhou, Fu-Xiang Hu, Liu He, Wei Li, Bai-Yu Zhu, Yan Jiang, Huan-Gang Zhou, Yun-Feng The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies |
title | The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies |
title_full | The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies |
title_fullStr | The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies |
title_full_unstemmed | The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies |
title_short | The MPO−463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case–Control Studies |
title_sort | mpo−463g>a polymorphism and lung cancer risk: a meta-analysis based on 22 case–control studies |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688689/ https://www.ncbi.nlm.nih.gov/pubmed/23840365 http://dx.doi.org/10.1371/journal.pone.0065778 |
work_keys_str_mv | AT yangjunping thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT wangwenbo thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT yangxiaoxi thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT yanglei thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT renli thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT zhoufuxiang thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT huliu thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT hewei thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT libaiyu thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT zhuyan thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT jianghuangang thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT zhouyunfeng thempo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT yangjunping mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT wangwenbo mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT yangxiaoxi mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT yanglei mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT renli mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT zhoufuxiang mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT huliu mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT hewei mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT libaiyu mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT zhuyan mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT jianghuangang mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies AT zhouyunfeng mpo463gapolymorphismandlungcancerriskametaanalysisbasedon22casecontrolstudies |